FDA approves AstraZeneca's Klygefa, a once-weekly self-injected myasthenia gravis drug
The FDA approved AstraZeneca's Klygefa (gefurulimab) for adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive. The once-weekly self-injected drug showed a 1.6-point improvement in MG-ADL score over placebo in a Phase 3 trial. AstraZeneca's Rare Disease unit had $7.5 billion in sales in the first nine months of 2026.
How this was made
The 30-second read
Why it matters
FDA approval is a direct regulatory milestone that can expand addressable demand by improving convenience versus IV dosing, while PREVAIL efficacy and safety support label confidence.
Market read
Traders can reassess AstraZeneca’s rare-disease growth outlook and competitive positioning in complement inhibition following a US label approval with Phase 3 efficacy and a differentiated delivery mechanism.
What to watch
The article does not provide US pricing or reimbursement details, which can dominate near-term revenue realization despite FDA approval.
Background
Klygefa (gefurulimab) is AstraZeneca’s once-weekly subcutaneous autoinjector C5 inhibitor for AChR-positive generalized myasthenia gravis, developed via its Alexion rare-disease unit.
Ticker impact
FDA approved AstraZeneca’s Klygefa (gefurulimab) for AChR-positive generalized myasthenia gravis, based on PREVAIL Phase 3 results.
Likely positive repricing as investors price in incremental revenue and reduced administration friction versus IV C5 inhibitors.
The article is a primary FDA approval with trial efficacy and a clear product differentiation (once-weekly autoinjector), which directly affects AstraZeneca’s product pipeline commercialization.
Market effects
Reinforces competitive momentum in complement C5 inhibition for autoimmune neuromuscular disease, with a shift toward patient-administered delivery.
US label approval can accelerate US prescribing and payer discussions, with follow-on impact as other regions’ approvals progress.
US approval may support global commercialization planning and manufacturing ramp decisions for a differentiated dosing format.
Counterpoint
Efficacy magnitude is modest (MG-ADL change difference), so market upside may be capped if payers or clinicians view it as incremental versus existing IV C5 inhibitors.
Key entities
- companyAstraZeneca
Sponsor of Klygefa (gefurulimab) and seller of existing C5 inhibitors Soliris and Ultomiris.
- drugKlygefa (gefurulimab)
First dual-binding nanobody C5 inhibitor approved in the US for AChR-positive gMG, dosed once weekly via autoinjector.
- clinical_trialPREVAIL Phase 3 trial
Randomized, double-blind, placebo-controlled study in 260 AChR-positive adults; primary endpoint MG-ADL change at week 26.
- regulatorFDA
Approved BLA 761488 for Klygefa under standard review.


